Research Article

Heme Oxygenase-1, a Key Enzyme for the Cytoprotective Actions of Halophenols by Upregulating Nrf2 Expression via Activating Erk1/2 and PI3K/Akt in EA.hy926 Cells

Xiu E. Feng, Tai Gang Liang, Jie Gao, De Peng Kong, Rui Ge, and Qing Shan Li

1School of Pharmaceutical Science, Shanxi Medical University, Taiyuan 030001, China
2Shanxi University of Traditional Chinese Medicine, Taiyuan 030024, China

Correspondence should be addressed to Qing Shan Li; sxlqs2012@163.com

Received 24 November 2016; Revised 23 February 2017; Accepted 12 April 2017; Published 14 June 2017

Academic Editor: Shane Thomas

Copyright © 2017 Xiu E. Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Increasing evidence has demonstrated that heme oxygenase-1 (HO-1) is a key enzyme triggered by cellular stress, exhibiting cytoprotective, antioxidant, and anti-inflammatory abilities. Previously, we prepared a series of novel active halophenols possessing strong antioxidant activities in vitro and in vivo. In the present study, we demonstrated that these halophenols exhibited significant protective effects against H2O2-induced injury in EA.hy926 cells by inhibition of apoptosis and ROS and TNF-α production, as well as induction of the upregulation of HO-1, the magnitude of which correlated with their cytoprotective actions. Further experiments which aimed to determine the mechanistic basis of these actions indicated that the halophenols induced the activation of Nrf2, Erk1/2, and PI3K/Akt without obvious effects on the phosphorylation of p38, JNK, or the expression of PKC-δ. This was validated with the use of PD98059 and Wortmannin, specific inhibitors of Erk1/2 and PI3K, respectively. Overall, our study is the first to demonstrate that the cytoprotective actions of halophenols involve their antiapoptotic, antioxidant, and anti-inflammatory abilities, which are mediated by the upregulation of Nrf2-dependent HO-1 expression and reductions in ROS and TNF-α generation via the activation of Erk1/2 and PI3K/Akt in EA.hy926 cells. HO-1 may thus be an important potential target for further research into the cytoprotective actions of halophenols.

1. Introduction

Vascular injury, including structural and functional impairment of the endothelium, is associated with an increased risk of developing various chronic inflammatory cardiovascular diseases, such as atherosclerosis, myocardial infarction, and hypertension [1, 2]. Various halophenols naturally derived from marine algae, ascidians, and sponges usually possess 1–4 benzene rings, in which halogen atoms and hydroxyls are linked by single covalent bonds [3–7]. Recently, many novel halophenols have been studied with growing interest due to their antioxidant, antimicrobial, antithrombotic, enzyme inhibitory, and cytotoxic activities, as well as their anti-inflammatory activities and protective effects on the vascular endothelium [8–12]. These promising biological properties have encouraged the development of efficient structural optimization and investigation into the mechanistic basis of halophenols. Using rational structural optimization, we recently prepared a series of novel halophenols with benzophenone, benzylbenzene, or furan-2-yl(phenyl)methanone skeletons, and we discovered three interesting compounds, namely halophenols 1 (HP1), 2 (HP2), and 3 (HP3) (Figure 1), with significant cytoprotective activities against H2O2-induced injury in human umbilical vein endothelial cells (HUVECs) [8, 9]. Additionally, further in vivo study showed that HP3 exhibited strong antiatherosclerotic and protective effects against myocardial ischemia-reperfusion injury in rats owing to its antioxidant, anti-inflammatory, and antiapoptotic abilities [13, 14].
Prolonged exposure to oxidative stress is an important cause and risk factor of many cardiovascular diseases. Heme oxygenase-1 (HO-1) is a stress-inducible rate-limiting enzyme that catalyzes the degradation of heme to generate biliverdin, free iron, and CO and plays a vital role in the defense and repair of oxidative stress-induced damage [15, 16]. Lack of HO-1 can cause profound changes in cellular homeostasis in genetically deficient mice and humans, which is associated with susceptibility to oxidative stress [17, 18]. In addition, HO-1 is also regarded as an important protein for anti-inflammatory and antiapoptotic actions [19–21] and therefore has become a potential target for the treatment of cardiovascular diseases with high oxidative stress levels, such as atherosclerosis, myocardial ischemia-reperfusion injury, hypertension, diabetes, and obesity [22–26].

The induction of HO-1 under oxidative stress is mainly activated by the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), which is regulated by the mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3k)/Akt, and protein kinase C (PKC) signaling pathways [27–32]. Increasing evidence has indicated that cytoprotective agents such as polyphenolic antioxidants can activate Nrf2 by interacting with Keap1 to release Nrf2 from the Keap1-Nrf2 complex [33–35]. Subsequent Nrf2 translocation into the nucleus and binding to the antioxidant response element (ARE) result in the transcriptional activation of phase II antioxidant enzymes, including HO-1 [36].

Considering the beneficial properties of halophenols as well as the possible key role of HO-1, in this study, we investigated the correlation between HO-1 activation and the cytoprotective actions of halophenols in H₂O₂-induced EA.hy926 cells and further explored the regulatory mechanism of associated upstream signaling pathways.

2. Materials and Methods

2.1. Materials. EA.hy926 cells were obtained from the Shanghai Institutes for Biological Sciences (Shanghai, China). We obtained 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and zinc protoporphyrin (ZnPP) from Sigma (St. Louis, MO, USA). TRIzol reagent was purchased from Life Technologies (Carlsbad, CA, USA). PD98059 and Wortmannin were purchased from Cell Signaling Technology (Danvers, MA, USA). The nuclear protein extraction kit was obtained from Beyotime Biotechnology Co. (Shanghai, China), and anti-Lamin B was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Prolonged exposure to oxidative stress is an important cause and risk factor of many cardiovascular diseases. Heme oxygenase-1 (HO-1) is a stress-inducible rate-limiting enzyme that catalyzes the degradation of heme to generate biliverdin, free iron, and CO and plays a vital role in the defense and repair of oxidative stress-induced damage [15, 16]. Lack of HO-1 can cause profound changes in cellular homeostasis in genetically deficient mice and humans, which is associated with susceptibility to oxidative stress [17, 18]. In addition, HO-1 is also regarded as an important protein for anti-inflammatory and antiapoptotic actions [19–21] and therefore has become a potential target for the treatment of cardiovascular diseases with high oxidative stress levels, such as atherosclerosis, myocardial ischemia-reperfusion injury, hypertension, diabetes, and obesity [22–26].

The induction of HO-1 under oxidative stress is mainly activated by the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), which is regulated by the mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3k)/Akt, and protein kinase C (PKC) signaling pathways [27–32]. Increasing evidence has indicated that cytoprotective agents such as polyphenolic antioxidants can activate Nrf2 by interacting with Keap1 to release Nrf2 from the Keap1-Nrf2 complex [33–35]. Subsequent Nrf2 translocation into the nucleus and binding to the antioxidant response element (ARE) result in the transcriptional activation of phase II antioxidant enzymes, including HO-1 [36].

Considering the beneficial properties of halophenols as well as the possible key role of HO-1, in this study, we investigated the correlation between HO-1 activation and the cytoprotective actions of halophenols in H₂O₂-induced EA.hy926 cells and further explored the regulatory mechanism of associated upstream signaling pathways.

2.2. Chemicals. Three halophenols, HP1, HP2, and HP3, were provided by our research group. Their purities were higher than 99.5%, as assessed by RP-HPLC on a column of Diamonsil C18 (250 mm × 4.6 mm, 5 μm) with a mobile phase of 70/10/20 methanol/acetonitrile/water (adjusted to pH3.0 with phosphoric acid), flow rate of 0.8 mL min⁻¹, column temperature of 25°C, injection volume of 20 μL, and detection wavelengths of 243 nm, 254 nm, and 261 nm for HP1, HP2, and HP3, respectively (Agilent 1200, Palo Alto, CA, USA). Compounds were dissolved in dimethyl sulfoxide (DMSO), stored at −20°C, and diluted to test concentrations with culture medium immediately prior to the experiment. The final concentration of DMSO in the culture medium was less than 0.1%.

2.3. Cell Culture. EA.hy926 cells were cultured in DMEM supplemented with 10% heat-inactivated FBS, penicillin (100 U/mL), and streptomycin (100 U/mL) at 37°C in a humidified atmosphere containing 95% air and 5% CO₂. All experiments were done following 6–12 passages.

2.4. Cell Viability Assay. An MTT assay was performed to estimate cell viability. Cells (1 × 10⁴ per well) were seeded in 96-well plates and cultured for 24 h, and then, the medium was replaced with fresh medium for different treatments. Next, 10 μL of 5 mg/mL MTT in phosphate-buffered saline (PBS) was added to each well, and cells were further incubated at 37°C for 4 h. Then, the culture medium was carefully removed, and 100 μL DMSO was added per well to dissolve the formed precipitate. Plates were shaken for 10 s, and OD values were measured at a wavelength of 490 nm on a Bio-Rad microplate reader (model 680, Bio-Rad, Hercules, CA, USA). Cell viability and cytoprotective rate were calculated using the following formulas, respectively: cell viability (%) = \( \frac{OD_{\text{Test}} - OD_{\text{Control}}} {OD_{\text{Control}}} \times 100\% \) and cytoprotective rate (%) = \( \frac{OD_{\text{Compound}} - OD_{\text{Model}}} {OD_{\text{Control}} - OD_{\text{Model}}} \times 100\% \).

2.5. Flow Cytometric Analysis of Apoptosis. An annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) double-staining kit (Life Technologies, Eugene, OR, USA) was used to detect apoptosis. After treatment with various
concentrations of HP3, HP2, HP1, and/or H2O2, EA.hy926 cells were collected and washed twice with ice-cold PBS and then resuspended in binding buffer at a concentration of 1 × 10^6 cells/mL. Then, 10 μL of annexin V-FITC and 10 μL of PI were added. The cells were incubated for 15 min in the dark, and analysis of apoptosis was then performed on a flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Early and late apoptotic cells were calculated based on annexin V positivity/PI negativity and annexin V positivity/PI positivity, respectively.

2.6. Determination of ROS and TNF-α Generation. Levels of intracellular ROS were examined using 2,7-dichlorofluorescein diacetate (DCFH-DA; Boster Biological Engineering Co.) by flow cytometric analysis. Cells were seeded on a 6-well plate. Twenty-four hours later, cells were treated with the compound for 6 h, exposed to 200 μM H2O2 for 30 min, washed twice with PBS, and then harvested with trypsin. Cells were subsequently incubated with 10 μM DCFH-DA for 30 min at 37°C and 5% CO2 and washed with PBS to remove all extracellular DCFH-DA; the fluorescence of dichlorofluorescein (DCF) was measured with flow cytometry (BD Biosciences, San Diego, CA, USA) [37].

Confluent cells in 24-well plates were pretreated with the compound for 6 h and subsequently incubated with 200 μM H2O2 for 30 min. TNF-α released into the medium was detected using an ELISA kit according to the manufacturer’s instructions. The relative ratios between the control and treatment groups were compared. This assay is able to detect concentrations as low as 1 pg/mL.

2.7. Preparation of Nuclear Proteins. According to the nuclear protein extraction protocol, 200 μL protein extraction reagent A containing 1 mM phenylmethylsulfonyl fluoride (PMSF) was added to each 20 μL of collected cell precipitation, vigorously vortexed for 5 s, and then left on ice for 15 min. Next, 10 μL protein extraction reagent B was added to the mixture, vigorously vortexed for 5 s, and placed on ice for another 1 min. After that, the solution was centrifuged at 12,000 ×g for 10 min at 4°C. After removal of the supernatant, 50 μL nuclear protein extraction reagent containing 1 mM PMSF was added to the nuclear precipitation, mixed, and vigorously vortexed for 15 s. The mixture was kept on ice for 30 min with periodic vortexing and was then centrifuged at 12,000 ×g for 10 min at 4°C. The supernatant was stored as the nuclear fraction for western blot analysis.

2.8. Western Blot Assay. After treatment, cells were washed with PBS and mixed with RIPA buffer containing 1 mM EDTA, 5 mg/mL aprotinin, 2 mg/mL leupeptin, and 1 mM PMSF, followed by centrifugation at 14,000 ×g for 15 min. Protein concentration was determined using a BCA kit (Boster Biological Engineering Co.). An equal amount of protein for each sample was resolved by performing 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then electrophoretically transferred onto nitrocellulose (NC) membranes (Millipore, Billerica, MA, USA). The membrane was blocked using 5% skim milk, incubated overnight at 4°C with primary antibody, and then washed three times for 10 min each with Tris-buffered saline containing 0.05% Tween 20 (TBST). Next, the membrane was incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibody and washed three times, followed by ECL detection (Boster Biological Engineering Co.) [38]. Western blotting data were quantified by Gel-Pro Analyzer 4.0, and each assay was conducted three times independently.

2.9. Statistical Analysis. All results are expressed as means ± standard deviations (SD). A one-way analysis of variance with Tukey’s post hoc test was performed using the Statistical Package for the Social Sciences software (SPSS 17.0 for Windows, 2010; SPSS Inc., Chicago, IL, USA). Values of P < 0.05 were considered to indicate statistical significance. All experiments were performed in triplicate.

3. Results

3.1. Halophenols Protect EA.hy926 Cells against H2O2-Induced Cell Death. The cytotoxicities of the three halophenols in the EA.hy926 cells were first examined by MTT assay at concentrations of 1, 5, 10, 20, and 40 μM. As shown in Figure 2(a), the three compounds had no effects on cell viability at concentrations between 1.0 μM and 20 μM for 24 h. We accordingly used concentrations of halophenols up to 20 μM in all additional experiments.

H2O2, a well-known cytotoxic molecule, was utilized to induce oxidative injury in EA.hy926 cells in the present study. There was a concentration-dependent decrease in cell viability after treatment with 50–600 μM H2O2 for 6 h (Figure 2(b)). Compared with cell viability in the control group, a concentration of 200 μM H2O2 caused about a 50% decrease in cell viability. Thus, 200 μM H2O2 was selected for subsequent assays.

HP3 pretreatment at concentrations below 10 μM attenuated H2O2-induced cell death in a dose-dependent manner (Figure 2(c)). Moreover, as shown in Figure 2(d), HP1, HP2, and HP3 at a concentration of 10 μM each exhibited potent cytoprotective activities, with cytoprotective rates of 63.3%, 65.8%, and 76.0%, respectively.

3.2. Flow Cytometric Analysis of Apoptosis. To determine whether the cytoprotective actions of halophenols are also involved in the inhibition of cell apoptosis, the effects of HP3, HP2, and HP1 on apoptosis following H2O2-induced injury in EA.hy926 cells were also evaluated by flow cytometric analysis in parallel with the MTT assay. As shown in Figure 3, the percentage of apoptotic cells (upper right) increased from 3.4% in the control group to 54.3% in the H2O2-only treated group. However, pretreatment of the cells with 1, 5, 10, and 20 μM HP3 significantly decreased rates of apoptosis induced by H2O2 to 31.7%, 37.4%, 17%, and 35%, respectively (Figure 3(j)). Pretreatment of cells with 10 μM HP2 and HP1 also significantly attenuated cell apoptosis induced by H2O2 to 22.8% and
These results suggest that HP1, HP2, and HP3 protect EA.hy926 cells against H_2O_2-induced apoptosis.

3.3. Halophenols Inhibit H_2O_2-Induced Production of ROS and TNF-α in EA.hy926 Cells. H_2O_2 causes cell damage by promoting the synthesis of several inflammatory mediators, including ROS and TNF-α. Therefore, we next examined whether the halophenols were capable of reducing ROS generation and TNF-α secretion in H_2O_2-induced EA.hy926 cells. As shown in Figure 4, intracellular ROS formation and TNF-α levels in the cell supernatant were significantly elevated after exposure to 200 μM H_2O_2. However, halophenol treatments efficiently reduced ROS and TNF-α levels in H_2O_2-treated cells, with the strongest effect exhibited by HP3, followed by HP2 and HP1, in accordance with their cytoprotective activities. These findings indicate that halophenols inhibit the H_2O_2-induced production of ROS and TNF-α in EA.hy926 cells.

3.4. HO-1 Is Involved in the Cytoprotective Actions of Halophenols. As HO-1 performs a vital function in the cellular defense against oxidative stress, we assessed whether the halophenols could induce HO-1 protein expression in relation to their cytoprotective actions. All three halophenols enhanced HO-1 protein expression at a concentration of 10 μM, with HP3 inducing the highest HO-1 expression, followed by HP2 and HP1 (Figure 5(a)). Interestingly, this order was consistent with their cytoprotective actions (Figure 5(b)). This demonstrates that there is likely a strong correlation between HO-1 activation and the cytoprotective actions of halophenols.
3.5. ZnPP, an Inhibitor of HO-1, Suppresses the Cytoprotective Effects of Halophenols against H₂O₂-Induced Cell Damage.

ZnPP, a specific inhibitor of HO-1, was used to further investigate whether HO-1 induction participated in the protective effects of halophenols against H₂O₂-induced cytotoxicity of EA.hy926 cells. Cells were treated with 10 μM ZnPP and then incubated with 10 μM halophenol for 6 h prior to treatment with 200 μM H₂O₂ for an additional 6 h [39]. MTT results demonstrated that the protective effects of the three halophenols against H₂O₂-induced cytotoxicity were reversed by the addition of ZnPP (Figure 6(a)). Analysis of intracellular ROS generation showed that ZnPP suppressed the ROS-scavenging activity of halophenols, and high TNF-α levels were restored in cell supernatants after ZnPP treatment.
treatment in the presence of halophenols and H$_2$O$_2$ (Figures 6(b) and 6(c)). This suggests that the induction of HO-1 protein expression participates in the actions of halophenols against H$_2$O$_2$-induced cell death and production of ROS and TNF-$\alpha$ in EA.hy926 cells. Taken together, the evidence indicates that the inhibition of ROS and TNF-$\alpha$ generation by halophenols is required for HO-1 activation. Moreover, HO-1 appears to play a key role in the cytoprotective actions of halophenols by inhibiting ROS and TNF-$\alpha$ generation.

3.6. HP3 Increases HO-1 Expression by Activating Nrf2. The nuclear translocation of activated Nrf2 is an important upstream contributor to the transcription of HO-1 [32]. Therefore, we selected HP3 to evaluate the role of Nrf2 in halophenol cytoprotection. To determine whether HP3 stimulates Nrf2 translocation in EA.hy926 cells, cells were treated with different concentrations of HP3 for 6 h, and the nuclear fractions were extracted for preparation of nuclear proteins. Nrf2 proteins in the cellular nuclear compartments were detected by western blotting. As shown in Figure 7(a),
HP3 enhanced nuclear Nrf2 expression in a concentration-dependent manner. Furthermore, consistent cytosolic protein expression of HO-1 was observed after HP3 treatment (Figure 7(b)). These results suggest that HP3-induced expression of HO-1 is mediated by activation of Nrf2 in EA.hy926 cells.

3.7. Involvement of Erk1/2 and Akt Kinase Pathways in HP3-Induced HO-1 Expression. MAPK cascades have been principally implicated in HO-1 activation. Many studies have suggested that the MAPK, PI3K/Akt, and PKC cascade pathways are involved in Nrf2 activation and translocation for the synthesis of highly specialized proteins, including HO-1. Subsequent experiments were designed to determine the possible roles of these pathways in HP3-induced HO-1 expression. As shown in Figures 8(a) and 8(b), HP3 treatment caused a concentration-dependent increase in the phosphorylation of Erk1/2 and Akt but had no effect on the expression of phosphorylated p38 (Figure 8(c)), phosphorylated JNK (Figure 8(d)), or PKC-δ (Figure 8(e)). In addition, when PD98059 (an inhibitor of Erk1/2) or Wortmannin (an inhibitor of PI3K) were added, HO-1 protein expression was significantly reduced compared to that in cells treated with HP3 alone (Figure 8(f)), confirming that the Erk1/2 and PI3K/Akt pathways participate in HP3-mediated HO-1 activation.

4. Discussion
The vascular endothelium is the major barrier of the cardiovascular system fighting against oxidative injury and inflammation, which is involved in the development of
Fig. 7: HP3 increases HO-1 expression by activating Nrf2 in EA.hy926 cells. (a) Induction of HP3 on nuclear Nrf2 expression. Cells were treated with HP3 at the indicated concentrations for 6 h. Nuclear extracts were prepared and 40 μg protein samples were subjected to western blot assay by using an anti-Nrf2 antibody or an anti-Lamin B (a nuclear protein marker) antibody. HP3 increased nuclear Nrf2 protein levels in a dose-dependent manner below 10 μM. (b) HP3 induced HO-1 expression in a concentration-dependent manner below 10 μM. **P < 0.01.

cardiovascular diseases including atherosclerosis, myocardial ischemia reperfusion, and hypertension [39]. The overproduction of ROS and TNF-α results from this oxidative stress [40, 41]. ROS production is tightly controlled by endogenous antioxidant systems; however, when endogenous antioxidants are overwhelmed by overproduction of ROS, oxidative stress occurs, resulting in inflammation and cellular damage [42]. This is characterized by the overproduction of inflammatory mediators, such as TNF-α and interleukin-6 (IL-6) [43].

In recent years, many novel halophenols have been reported for their wide spectra of bioactivities, including antioxidant, antithrombotic, antimicrobial, anti-inflammatory, enzyme inhibitory, cytotoxic, and feeding-deterrent activities [3–7, 44]. In our previous research, a series of benzophenone, benzylbenzene, and furan-2-yl(phenyl) methanone halophenols were prepared [8, 9]. Among these, three benzophenone halophenols, HP1, HP2, and HP3, exhibited strong antioxidant properties. In particular, HP3 also showed significant antiatherosclerotic and protective effects against myocardial ischemia-reperfusion injury in rats [8, 13, 14]. The attenuation of oxidative stress has been suggested to contribute to the cardiovascular benefits of active halophenols, implying that halophenols have potential value in the treatment of oxidative stress-associated cardiovascular diseases. This information prompted us to investigate whether there were significant correlations between the cytoprotective actions of halophenols and their antioxidant capabilities.

Although primary endothelial cells are widely considered a superior model for studying of endothelial cell biology than other cell lines, they may require complex growth medium and undergo phenotypic change with passages. Nowadays, EA.Hy926 cell line generated by the fusion of HUVECs with the human lung carcinoma cell line A549 is also widely used for researches of vascular endothelial protective activities of chemical substances in vitro due to its expression of some factors such as VIII-related antigen (VIII:Ag) [45, 46], Weibel-Palade bodies [47], Von Willebrand factor [45], α-granule membrane protein (GMP-140) [48], prostacyclin [49], platelet activating factor [50], tissue plasminogen activator, plasminogen activator inhibitor type 1 [51], thrombomodulin [52], vitronectin receptor [53], and modified low-density lipoproteins [52], which are similar to those expressed by primary endothelial cells. Zhao et al. employed EA.Hy926 cells to establish H2O2-mediated oxidative injury model for evaluation of the protective effects of pranlukast, which was associated with the inhibition of ROS-mediated collapse of mitochondrial membrane potential [54]. Wang et al. used EA.hy926 cells exposed to H2O2 to investigate the protective role of 7,8-dihydroxyflavone, which acted by inhibiting cell apoptosis, inflammatory factor releasing, and ROS level via binding to TrkB receptor [55]. Tian et al. synthesized quercetin 7-O-sialic acid and evaluated its protective effects against endothelial damage. To select a suitable concentration of H2O2 exposure, we treated cells with 50–600 μM H2O2 for 6 h and measured the cell survival. The results showed that exposure of EA.hy926 cells to 200 μM H2O2 for 6 h caused a reduction of cell survival in a modest but readily detectable manner. There were reported that the concentration of H2O2 frequently used to induce oxidative stress was ranging from 10 to 1000 μM [57–60]. Fan et al. treated HUVECs with 200 μM H2O2 to induce oxidative stress.
stress and revealed that the protective effects of *Panax notoginseng* saponins and Ginsenoside Rb1 on endothelial cells were associated with the activation of Nrf2, which mediated the suppress of monocyte adhesion events via the inhibition of the ROS-TNF-α-p38-VCAM-1 pathway [61]. Qiao et al. treated HUVECs with 400 μM H₂O₂ and demonstrated that polydatin can protect HUVECs against oxidative injury by inhibition of oxidative stress and cell apoptosis via various interactions with PKC pathway [39]. On the other hand, Lacy et al. reported that human plasma contained 1–8 μM H₂O₂ (with an average of ~3 μM) under physiological condition by comparing the plasma hydrogen peroxide production of normotensive and hypertensive members [62]. Hyslop et al. found that H₂O₂ levels can attain 100–160 μM during acute vascular pathology such as ischemia/reperfusion of rats [63]. High levels of vascular H₂O₂ were also observed in the transient and progressive vascular pathologies of wounds and hyperglycemia, respectively [58, 64]. That is, high-levels of H₂O₂ may be linked to some specific disease conditions where severe inflammation is evident.

In the following experiments, the dosing regimen of halophenols was considered in relation to the physiological

| Figure 8: Mediation of HP3 on MAPK, PI3K/Akt, and PKC signaling pathways. (a) HP3 induced Erk1/2 phosphorylation in a concentration-dependent manner. (b) HP3 induced Akt phosphorylation in a concentration-dependent manner. (c) HP3 had no influence on p38 phosphorylation. (d) HP3 had no influence on JNK phosphorylation. (e) HP3 had no influence on PKC-δ protein expression. (f) Influences of the inhibitors PD98059 and Wortmannin on HO-1 expression. The uses of inhibitors significantly reduced HO-1 expression compared to those of treatment with HP3 alone. **P < 0.01. |
actions and future clinical applications. Previously, we investigated the pharmacokinetics of HP3 in rats by oral administration HP3-solid dispersion (PVP-K30 as dispersing carrier), and the results showed that most plasma concentration values in 24 h after oral administration were kept around 10 μM (unpublished). Additionally, MTT assay showed that a 10 μM concentration of halophenols exhibited no significant cytotoxicity (Figure 2(a)). Therefore, we designated that the doses of the compounds were below 10 μM in present research.

HO-1, a key antioxidant enzyme, has been recognized as a major component of the cellular defense system against oxidative stress and plays an essential role in the pathogenesis of cardiovascular diseases [44, 65–70]. Until now, it has remained unclear whether the induction of HO-1 was involved in the cytoprotective actions of halophenols. Accordingly, the effects of HP1, HP2, and HP3 on HO-1 protein expression were determined, and we further investigated the roles of associated signaling pathways in HO-1 activation. ZnPP is one of the most commonly used specific inhibitors of HO-1 and can reverse the protective effect of the drug against H2O2-induced injury at the cell level by influencing the activity and expression of HO-1. Thus, we selected the ZnPP as an inhibitor of HO-1 to investigate the relevance between the HO-1 activation and cytoprotective actions of halophenols. The ZnPP concentration used is not always consistent in the literature including 1, 5, 10, and 20 μM [66, 71]. By our preliminary experiment, we found that 10 μM ZnPP exhibited the most significant inhibition on the protective effects of halophenols. We thus determined 10 μM as ZnPP concentration for this study. Our results showed that the active halophenols markedly induced upregulation of HO-1 (Figure 5(a)) and decreased intracellular levels of ROS and TNF-α (Figure 4). Conversely, inhibition of HO-1 by ZnPP significantly prevented the protective effects of halophenols against oxidative damage (Figure 6). Moreover, the magnitude of the induction of HO-1 by the three halophenols was correlated with their cytoprotective activities, with HP3 having the greatest effect, followed by HP2 and HP1 (Figure 5(b)). This confirms that the protective actions of the halophenols on vascular endothelial cells are closely associated with their antioxidant capabilities, as well as verifying that HO-1 is a key antioxidant enzyme involved in the cytoprotective actions of halophenols.

Nrf2 is a key regulator of endogenous antioxidant defense, and Nrf2-dependent phase II enzymes play a pivotal role in preventing oxidative stress, chronic inflammation, and atherosclerotic pathogenesis [44, 65–67, 72]. The anti-inflammatory effects of phase II antioxidant enzymes are associated with the modulation of ROS generation and removal. Among these proteins, HO-1 is a potent antioxidant enzyme, catalyzing the conversion of heme to the biologically active products CO and biliverdin/bilirubin, which regulate redox balance, and enhancing cellular survival. This heme-

Figure 9: Diagram of the proposed molecular mechanism of HP3 in the induction of HO-1 to protect against oxidative stress injury in EA.hy926 cells.
degrading protein also activates alternate cell survival pathways that inhibit apoptosis.

In conclusion, the antiapoptotic, antioxidant, and anti-inflammatory abilities of halophenols contribute to their cytoprotective actions against H$_2$O$_2$-induced injury in EA.hy926 cells. In this process, HO-1 acts as a key inducible enzyme. The protective actions of active halophenols are mediated by the upregulation of Nrf2-dependent HO-1 expression and reductions in ROS and TNF-α generation via activation of the Erk1/2 and PI3K/Akt signaling pathways in EA.hy926 cells (Figure 9). Our findings reveal that HO-1 may be an important potential target for further structural optimization of active halophenol derivatives in the development of treatments for oxidative stress-associated cardiovascular diseases.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

Qing Shan Li and Xiu E. Feng conceived and designed the experiments. Xiu E. Feng wrote the manuscript. Tai Gang Liang helped draft the final manuscript. Jie Gao and De Peng Kong performed the experiments. Rui Ge helped in the preparation of experiments. All authors reviewed and approved the final manuscript. Xiu E. Feng, Tai Gang Liang, and Jie Gao contributed equally as first authors.

Acknowledgments

This work was financially supported by the State “863” Projects of China (no. 2013AA092903), the National Natural Science Foundation of China (no. 81473100), the Natural Science Foundation of Shanxi Province (201301060-2), Shanxi Medical University Doctor Startup Fund (B03201213), the Program for the Top and Key Science and Technology Innovation Teams of Shanxi Province, and the Program for the Top Young and Middle-Aged Innovative Talents of Higher Learning Institutions of Shanxi Province.

References

[1] A. C. Roberts and K. E. Porter, “Cellular and molecular mechanisms of endothelial dysfunction in diabetes,” *Diabetes & Vascular Disease Research*, vol. 10, no. 6, pp. 472–482, 2013.

[2] J. H. Ip, V. Fuster, L. Badimon, J. Badimon, M. B. Taubman, and J. H. Chesebro, “Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation,” *Journal of the American College of Cardiology*, vol. 15, no. 7, pp. 1667–1687, 1990.

[3] K. Li, X. N. Li, and B. Wang, “Natural bromophenols from the marine red alga *Polysiphonia urceolata* (Rhodomelaceae): structural elucidation and DPPH radical-scavenging activity,” *Bioorganic and Medicinal Chemistry*, vol. 15, no. 21, pp. 6627–6631, 2007.

[4] X. Xu, F. H. Song, S. J. Wang et al., “Dibenzyl bromophenols with diverse dimerization patterns from the brown alga *Leathesia nana*,” *Journal of Natural Products*, vol. 67, no. 10, pp. 1661–1666, 2004.

[5] D. F. Wiemer, D. D. Idler, and W. Fenical, “Vidalols A and B, new anti-inflammatory bromophenols from the Caribbean marine red alga *Vidalia obtusolaba*,” *Experientia*, vol. 47, no. 8, pp. 851–853, 1991.

[6] W. Wang, Y. Okada, H. Shi, Y. Wang, and T. Okuyama, “Structures and aldose reductase inhibitory effects of bromophenols from the red alga *Symphyocladia laticaulis*,” *Journal of Natural Products*, vol. 68, no. 4, pp. 620–622, 2005.

[7] K. Kurata, K. Taniguchi, K. Takashima, I. Hayashi, and M. Suzuki, “Feeding-deterrent bromophenols from *Odonthalia corymbifera*,” *Phytochemistry*, vol. 45, no. 3, pp. 485–487, 1997.

[8] W. Y. Zhao, X. E. Feng, S. R. Ban, W. Lin, and Q. Li, “Synthesis and biological activity of halophenols as potent antioxidant and cytoprotective agents,” *Bioorganic & Medicinal Chemistry Letters*, vol. 20, no. 14, pp. 4132–4134, 2010.

[9] F. L. Zheng, S. R. Ban, X. E. Feng, C. Zhao, G. Du, and Q. Li, “Synthesis and biological activities of new halophenols,” *Medicinal Chemistry*, vol. 9, no. 2, pp. 303–311, 2013.

[10] N. Oztaskin, Y. Cetinkaya, P. Taslimi, S. Göksu, and I. Gülcin, “Antioxidant and acetylcholinesterase inhibition properties of novel bromophenol derivatives,” *Bioorganic Chemistry*, vol. 60, pp. 49–57, 2015.

[11] B. P. Bandgar, S. A. Patil, J. V. Totre et al., “Synthesis and biological evaluation of nitrogen-containing benzophenone analogues as TNF-α and IL-6 inhibitors with antioxidant activity,” *Bioorganic & Medicinal Chemistry Letters*, vol. 20, no. 7, pp. 2292–2296, 2010.

[12] G. A. E. I. Shoubaky, M. M. Abdel-Daim, M. H. Mansour, and E. A. Salem, “Isolation and identification of a flavone apigenin from marine red alga *Acanthophora spicifera* with antiinociceptive and anti-inflammatory activities,” *Journal of Experimental Neuroscience*, vol. 10, pp. 21–29, 2016.

[13] Q. S. Li, Y. Wang, X. E. Feng, and L. G. Han, *The Application of Two Bromophenols and their Medicinal Salts as the Drugs Against the Myocardial Ischemia Reperfusion Injury*, State Intellectual Property Office of the P.R.C., Beijing, China, 2013.

[14] Q. S. Li, X. E. Feng, and S. R. Ban, *The Application of Polyhydroxyl Bromo- Diphenylketone Compounds and their Derivatives in the Treatment and Prevention of Atherosclerosis*, State Intellectual Property Office of the P.R.C., Beijing, China, 2014.

[15] H. J. Duckers, M. Boehm, A. L. True et al., “Heme oxygenase-1 protects against vascular constriction and proliferation,” *Nature Medicine*, vol. 7, no. 6, pp. 693–698, 2001.

[16] M. H. Ghattas, L. T. Chuang, A. Kappas, and N. G. Abraham, “Protective effect of HO-1 against oxidative stress in human hepatoma cell line (HepG2) is independent of telomerase enzyme activity,” *International Journal of Biochemistry & Cell Biology*, vol. 34, no. 12, pp. 1619–1628, 2002.

[17] K. D. Poss and S. Tonegawa, “Reduced stress defense in heme oxygenase 1-deficient cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 20, pp. 10925–10930, 1997.

[18] A. Yachie, Y. Niida, T. Wada et al., “Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency,” *Journal of Clinical Investigation*, vol. 103, no. 1, pp. 129–135, 1999.

[19] M. D. Maines, G. M. Trakshel, and R. K. Kutty, “Characterization of two constitutive forms of rat liver microsomal...
heme oxygenase. Only one molecular species of the enzyme is inducible," *Journal of Biological Chemistry*, vol. 261, no. 1, pp. 411–419, 1986.

[20] W. K. McCoubrey, T. J. Huang, and M. D. Maines, "Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3," *European Journal of Biochemistry*, vol. 247, no. 2, pp. 725–732, 1997.

[21] H. G. Lee, M. H. Li, E. J. Joung, H. K. Na, Y. N. Cha, and Y. J. Suh, "Nrf2-mediated heme oxygenase-1 upregulation as adaptive survival response to glucose deprivation-induced apoptosis in HepG2 cells," *Antioxidants & Redox Signaling*, vol. 13, no. 11, pp. 1639–1648, 2010.

[22] S. W. Ryter, J. Alam, and A. M. K. Choi, "Heme oxygenase-1 carbon monoxide: from basic science to therapeutic applications," *Physiological Reviews*, vol. 86, no. 2, pp. 583–650, 2006.

[23] N. G. Abraham and A. Kappas, "Pharmacological and clinical aspects of heme oxygenase," *Pharmacological Reviews*, vol. 60, no. 1, pp. 79–127, 2008.

[24] A. Jazwa and A. Cuadrado, "Targeting heme oxygenase-1 for neuroprotection and neuroinflammation in neurodegenerative diseases," *Current Drug Targets*, vol. 11, no. 12, pp. 1517–1531, 2010.

[25] W. Durante, "Targeting heme oxygenase-1 in vascular disease," *Current Drug Targets*, vol. 11, no. 12, pp. 1504–1516, 2010.

[26] P. A. Hosick and D. E. Stoc, "Heme oxygenase, a novel target for the treatment of hypertension and obesity?" *American Journal of Physiology Regulatory Integrative & Comparative Physiology*, vol. 302, no. 2, pp. R207–R214, 2012.

[27] J. L. Wu, H. Y. Wang, Y. L. Cheng, C. Du, and H. Qian, "Neuroprotective effects of taurourhodin against H2O2-induced oxidative injury and apoptosis in PC12 cells," *Die Pharmazie*, vol. 70, no. 1, pp. 17–23, 2015.

[28] J. S. Kang, M. H. Han, G. Y. Kim et al., "Schisandrae semen essential oil attenuates oxidative stress-induced cell damage in C2C12 murine skeletal muscle cells through Nrf2-mediated upregulation of HO-1," *International Journal of Molecular Medicine*, vol. 35, no. 2, pp. 453–459, 2015.

[29] T. H. N. Ho-Bouloise, A. Clapéron, M. Merger et al., "Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells," *Free Radical Biology & Medicine*, vol. 89, pp. 34–46, 2015.

[30] B. J. Buckley, Z. M. Marshall, and A. R. Whorton, "Nitric oxide stimulates Nrf2 nuclear translocation in vascular endothelium," *Biochemical & Biophysical Research Communications*, vol. 307, no. 4, pp. 973–979, 2003.

[31] J. S. Chen, P. H. Huang, C. H. Wang et al., "Nrf-2 mediated heme oxygenase-1 expression, an antioxidant-independent mechanism, contributes to anti-atherogenesis and vascular protective effects of Ginkgo biloba extract," *Atherosclerosis*, vol. 214, no. 2, pp. 301–309, 2011.

[32] Y. M. Kim, H. O. Pae, J. E. Park et al., "Heme oxygenase in the regulation of vascular biology: from molecular mechanisms to therapeutic opportunities," *Antioxidants & Redox Signaling*, vol. 14, no. 1, pp. 137–167, 2011.

[33] K. Itoh, N. Wakabayashi, Y. Katoh et al., "Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain," *Genes & Development*, vol. 13, no. 1, pp. 76–86, 1999.

[34] A. T. Dinkova-Kostova and P. Talalay, "Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulphydryl groups," *Proceedings of the National Academy of Sciences*, vol. 98, no. 6, pp. 3404–3409, 2001.

[35] A. T. Dinkova-Kostova, W. D. Holtzclaw, R. N. Cole et al., "Direct evidence that sulphydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 18, pp. 11908–11913, 2002.

[36] N. Wakabayashi, A. T. Dinkova-Kostova, W. D. Holtzclaw et al., "Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 7, pp. 2040–2045, 2004.

[37] T. Chen, Z. P. Guo, X. Y. Jiao, Y. H. Zhang, J. Y. Li, and H. J. Liu, "Protective effects of peoniflorin against hydrogen peroxide-induced oxidative stress in human umbilical vein endothelial cells," *Canadian Journal of Physiology & Pharmacology*, vol. 89, no. 6, pp. 445–453, 2011.

[38] E. Mitchell, A. Kiska, and J. Y. Pan, "IL-4 western blot analysis of high fat diet and control diet Sprague Dawley rats," i-ACES, vol. 1, no. 1, pp. 86–90, 2014.

[39] H. L. Qiao, H. Chen, Y. H. Dong et al., "Polydatin attenuates H2O2-induced oxidative stress via PKC pathway," *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 5139458, 10 pages, 2016.

[40] V. Fuchs-Tarlovsky, "Role of antioxidants in cancer therapy," *Nutrition*, vol. 29, no. 1, pp. 15–21, 2013.

[41] S. Wassmann, U. Laufs, A. T. Bäumer et al., "HMGo-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species," *Hypertension*, vol. 37, no. 6, pp. 1450–1457, 2001.

[42] S. Lee, Y. Park, M. Y. Zuidema, M. Hannink, and C. Zhang, "Effects of interventions on oxidative stress and inflammation of cardiovascular diseases," *World Journal of Cardiology*, vol. 3, no. 1, pp. 18–24, 2011.

[43] O. Benavente-Garcia and J. Castillo, "Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity," *Journal of Agricultural & Food Chemistry*, vol. 56, no. 15, pp. 6185–6205, 2008.

[44] A. Nikam, A. Ollivier, M. Rivard et al., "Diverse Nrf2 activators coordinated to cobalt carboxyls induce heme oxygenase-1 and release carbon monoxide in vitro and in vivo," *Journal of Medicinal Chemistry*, vol. 59, no. 2, pp. 756–762, 2016.

[45] C. J. Edgell, C. C. Mcdonald, and J. B. Graham, "Permanent cell line expressing human factor VIII-related antigen established by hybridization," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 80, no. 12, pp. 3734–3737, 1983.

[46] D. Bous, G. A. P. Hospers, C. Meijer, G. Molema, and N. H. Mulder, "Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research," *Angiogenesis*, vol. 4, no. 2, pp. 91–102, 2001.

[47] C. J. Edgell, J. E. Haizlip, C. R. Bagnell et al., "Endothelium specific Weibel-Palade bodies in a continuous human cell line, EA.hy926," *In Vitro Cellular and Developmental Biology - Plant*, vol. 26, no. 12, pp. 1167–1172, 1990.
[48] G. I. Johnston, R. G. Cook, and R. P. Mcever, “Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation,” Cell, vol. 56, no. 6, pp. 1033–1044, 1989.

[49] J. E. Suggs, M. C. Madden, M. Friedman, and C. J. Edgell, “Prostacyclin expression by a continuous human cell line derived from vascular endothelium,” Blood, vol. 68, no. 4, pp. 825–829, 1986.

[50] B. Bussolino, P. Biffignandi, and P. Arese, “Platelet-activating factor - a powerful lipid autacoid possibly involved in microangiopathy,” Acta Haematologica, vol. 75, no. 3, pp. 129–140, 1986.

[51] J. J. Emeis and C. J. Edgell, “Fibrinolytic properties of a human endothelial hybrid cell line (EA.hy926),” Blood, vol. 71, no. 6, pp. 1669–1675, 1988.

[52] A. Beretz, J. M. Freyssinet, J. Gauchy et al., “Stability of the thrombin-thrombomodulin complex on the surface of endothelial cells from human saphenous vein or from the cell line EA.hy926,” Biochemical Journal, vol. 259, no. 1, pp. 35–40, 1989.

[53] K. R. Fath, C. J. Edgell, and K. Burridge, “The distribution of distinct integrins in focal contacts is determined by the substratum composition,” Journal of Cell Science, vol. 92, Part 1, pp. 67–75, 1990.

[54] R. Zhao, S. H. Fang, K. N. Lin et al., “Pralnukast attenuates hydrogen peroxide-induced necrosis in endothelial cells by inhibiting oxygen reactive species-mediated collapse of mitochondrial membrane potential,” Journal of Cardiovascular Pharmacology, vol. 57, no. 4, pp. 479–488, 2011.

[55] B. X. Wang, Q. Zhang, R. Y. Yao, X. Liu, and Z. Qu, “7, 8-dihydroxyflavone protects an endothelial cell line from H2O2 damage,” PloS One, vol. 10, no. 8, article e0135345, 2015.

[56] H. Tian, Q. C. Liu, S. C. Qin et al., “Synthesis and cardiovascular protective effects of quercetin 7-O-sialic acid,” Journal of Cellular and Molecular Medicine, vol. 21, no. 1, pp. 107–120, 2017.

[57] H. Patel, J. Chen, and M. Kavadia, “Induced peroxidase and cytoprotective enzyme expressions support adaptation of HUVECs to sustain subsequent H2O2 exposure,” Microvascular Research, vol. 103, pp. 1–10, 2016.

[58] K. F. Smir, R. P. Kerindongo, A. Boing et al., “Effects of helium on inflammatory and oxidative stress-induced endothelial cell damage,” Experimental Cell Research, vol. 337, no. 1, pp. 37–43, 2015.

[59] Y. L. Xu, J. Zhu, X. Hu et al., “CLIC1 inhibition attenuates vascular inflammation, oxidative stress, and endothelial injury,” PloS One, vol. 11, no. 11, article e0166790, 2016.

[60] J. K. Li, R. Ge, C. X. Zhao, L. Tang, J. Li, and Q. Li, “Farrerol regulates ocludin expression in hydrogen peroxide-induced EA.hy926 cells by modulating ERK 1/2 activity,” European Journal of Pharmacology, vol. 734, pp. 9–14, 2014.

[61] J. S. Fan, D. N. Liu, C. Y. He, X. Li, and F. He, “Inhibiting adhesion events by Panax notoginseng saponins and Ginsenoside Rb1 protecting arteries via activation of Nrf2 and suppression of p38-VCAM-1 signal pathway,” Journal of Ethnopharmacology, vol. 192, pp. 423–430, 2016.

[62] F. Lacy, M. T. Kailasam, D. T. O’Connor, G. W. Schmid-Schönbein, and R. J. Parmer, “Plasma hydrogen peroxide production in human essential hypertension role of heredity, gender, and ethnicity,” Hypertension, vol. 36, no. 5, pp. 878–884, 2000.